ALLOGENE THERAPEUTICS INC (ALLO)
US0197701065 - Common Stock
ALLO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. While ALLO seems to be doing ok healthwise, there are quite some concerns on its profitability. ALLO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
ALLO had negative earnings in the past year.
In the past year ALLO has reported a negative cash flow from operations.
In the past 5 years ALLO always reported negative net income.
ALLO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -89.10%, ALLO is not doing good in the industry: 72.53% of the companies in the same industry are doing better.
ALLO has a Return On Equity (-113.19%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -89.1% | ||
| ROE | -113.19% | ||
| ROIC | N/A |
ROA(3y)-38.79%
ROA(5y)-32.49%
ROE(3y)-47.3%
ROE(5y)-38.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ALLO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALLO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALLO has been increased compared to 5 years ago.
There is no outstanding debt for ALLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -4.36, we must say that ALLO is in the distress zone and has some risk of bankruptcy.
ALLO's Altman-Z score of -4.36 is on the low side compared to the rest of the industry. ALLO is outperformed by 60.14% of its industry peers.
There is no outstanding debt for ALLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.36 |
ROIC/WACCN/A
WACC10.59%
2.3 Liquidity
A Current Ratio of 9.35 indicates that ALLO has no problem at all paying its short term obligations.
The Current ratio of ALLO (9.35) is better than 78.99% of its industry peers.
A Quick Ratio of 9.35 indicates that ALLO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 9.35, ALLO is in the better half of the industry, outperforming 79.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.35 | ||
| Quick Ratio | 9.35 |
3. Growth
3.1 Past
ALLO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.93%, which is quite impressive.
ALLO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -35.00%.
EPS 1Y (TTM)33.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.51%
Revenue 1Y (TTM)-35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
The Earnings Per Share is expected to grow by 12.72% on average over the next years. This is quite good.
ALLO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 373.14% yearly.
EPS Next Y31.24%
EPS Next 2Y14.52%
EPS Next 3Y8.04%
EPS Next 5Y12.72%
Revenue Next Year-53.17%
Revenue Next 2Y-42.26%
Revenue Next 3Y178.55%
Revenue Next 5Y373.14%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ALLO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALLO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.52%
EPS Next 3Y8.04%
5. Dividend
5.1 Amount
No dividends for ALLO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALLOGENE THERAPEUTICS INC
NASDAQ:ALLO (1/2/2025, 11:45:49 AM)
2.335
+0.21 (+9.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners67.46%
Inst Owner Change-0.3%
Ins Owners7.07%
Ins Owner Change-0.15%
Market Cap489.58M
Analysts81.74
Price Target9.22 (294.86%)
Short Float %22.22%
Short Ratio12.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.98%
Min EPS beat(2)1.21%
Max EPS beat(2)4.75%
EPS beat(4)4
Avg EPS beat(4)5.27%
Min EPS beat(4)1.21%
Max EPS beat(4)8.99%
EPS beat(8)7
Avg EPS beat(8)7.8%
EPS beat(12)11
Avg EPS beat(12)8.9%
EPS beat(16)15
Avg EPS beat(16)10.3%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-21.99%
Min Revenue beat(4)-100%
Max Revenue beat(4)124.67%
Revenue beat(8)4
Avg Revenue beat(8)79.34%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.46%
PT rev (3m)-5.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.11%
EPS NY rev (1m)-0.28%
EPS NY rev (3m)10.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.63%
Revenue NY rev (1m)2.13%
Revenue NY rev (3m)-6.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4184.44 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.06 | ||
| P/tB | 1.06 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.48
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS0
BVpS2.21
TBVpS2.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -89.1% | ||
| ROE | -113.19% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-38.79%
ROA(5y)-32.49%
ROE(3y)-47.3%
ROE(5y)-38.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.41% | ||
| Cap/Sales | 523.93% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.35 | ||
| Quick Ratio | 9.35 | ||
| Altman-Z | -4.36 |
F-Score2
WACC10.59%
ROIC/WACCN/A
Cap/Depr(3y)84.08%
Cap/Depr(5y)426.61%
Cap/Sales(3y)1271.34%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.51%
EPS Next Y31.24%
EPS Next 2Y14.52%
EPS Next 3Y8.04%
EPS Next 5Y12.72%
Revenue 1Y (TTM)-35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-53.17%
Revenue Next 2Y-42.26%
Revenue Next 3Y178.55%
Revenue Next 5Y373.14%
EBIT growth 1Y-50.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.07%
EBIT Next 3Y-1.69%
EBIT Next 5Y1.54%
FCF growth 1Y-4.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.6%
OCF growth 3YN/A
OCF growth 5YN/A